© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 4, 319,
February 21, 2001
© 2001 Oxford University Press
CORRESPONDENCE |
Re: Multiple Births and Risk of Epithelial Ovarian Cancer
Affiliations of authors: C. La Vecchia, Istituto di Statistica Medica e Biometria, Università degli Studi di Milan, Italy; E. Negri, Istituto di Ricerche Farmacologiche "Mario Negri," Milan; R. Talamini, Centro di Riferimento Oncologico, Aviano, Italy; E. Conti, Istituto Regina Elena per lo Studio e la Cura dei Tumori, Rome, Italy; M. Montella, Istituto Tumori "Fondazione Pascale," Naples, Italy; S. Franceschi, International Agency for Research on Cancer, Lyon, France.
Correspondence to: Eva Negri, Sc.D., Istituto di Ricerche Farmacologiche "Mario Negri," Via Eritrea 62, 20157 Milan, Italy (e-mail: evanegri{at} marionegri.it).
Multiple births may influence ovarian cancer risk, since they may reflect higher levels of gonadotropins or multiple ovulations, which have been related to ovarian carcinogenesis (1–3). The issue, moreover, is of specific interest in consideration of the debate on the possible role of fertility drugs, which stimulate ovulation, in ovarian carcinogenesis (4,5). A pooled analysis of eight studies conducted in the United States, Canada, and Australia and published in the journal, however, found no material association between multiple births and ovarian cancer risk (6).
To provide further information on the issue, we have, therefore, considered data from a multicentric case–control study conducted from January 1992 through September 1999 in greater Milan and the provinces of Pordenone and Gorizia in northern Italy, the province of Latina in central Italy, and the urban area of Naples in southern Italy (7).
Briefly, case patients were 1031 women admitted to the major teaching and general hospitals of the study areas, with incident, histologically confirmed epithelial ovarian cancer. The age range was 18–79 years, and the median age 57 years. Control subjects were 2441 women (age range, 17–79 years; median age, 57 years) with no history of cancer who were admitted to hospitals in the same areas as case patients for acute, non-neoplastic, nongynecologic conditions (26% traumas, 28% nontraumatic orthopedic diseases, 15% surgical conditions, and 31% miscellaneous other diseases). The distributions of case patients and control women were similar in terms of age and area of residence.
Information on reproductive factors included number of births (singleton and multiple), abortions, and stillbirths and age at each birth. Odds ratios (ORs) for multiple births and the corresponding 95% confidence intervals (CIs) were computed by use of multiple logistic regression models. The regression equation model included terms for age in 5-year intervals, area of residence, years of education, parity, menopausal status/age at menopause, family history of breast and ovarian cancers, and oral contraceptive use.
A total of 17 (1.6%) case patients and 41 (1.7%) control subjects had ever had multiple births. Only two control women and one case patient had more than one multiple birth; only one control had triplets. Compared with parous women with only singleton births, the multivariate OR for ovarian cancer for women with multiple births was 0.89 (95% CI = 0.48 to 1.24; Table 1
). No significant heterogeneity was evident across strata of parity (OR = 0.70; 95% CI = 0.26 to 1.86 for women with one or two births; OR = 1.20 and 95% CI = 0.53 to 2.63 for those with three births). Only one (1.2%) of 81 women with mucinous ovarian cancer reported multiple births.
|
Our findings confirm that multiple births do not appear to influence subsequent ovarian cancer risk (6), regardless of the number of births. Multiple births were comparably rare in our dataset. Apart from the baseline characteristics of the population, this indicates that ovulation-inducing drugs (4,5) were not common in Italy in the generations of women included in this study.
REFERENCES
1 Lambalk CB, De Koning CH, Braat DD. The endocrinology of dizygotic twinning in the human. Mol Cell Endocrinol 1998;145:97–102.[CrossRef][ISI][Medline]
2
La Vecchia C, Franceschi S, Gallus S, Decarli, Liberati A, Tognoni G. Incessant ovulation and ovarian cancer: a critical approach. Int J Epidemiol 1983;12:161–4.
3 Parazzini F, Franceschi S, La Vecchia C, Fasoli M. The epidemiology of ovarian cancer. Gynecol Oncol 1991;43:9–23.[CrossRef][ISI][Medline]cancerlit;92070750
4
Parazzini F, Negri E, La Vecchia C, Moroni S, Franceschi S, Crosignani PG. Treatment for infertility and risk of invasive epithelial ovarian cancer. Hum Reprod 1997;12:2159–61.
5
Glud E, Kjaer SK, Troisi R, Brinton LA. Fertility drugs and ovarian cancer. Epidemiol Rev 1998;20:237–57.
6
Whiteman DC, Murphy MF, Cook LS, Cramer DW, Hartge P, Marchbanks PA, et al. Multiple births and risk of epithelial ovarian cancer. J Natl Cancer Inst 2000;92:1172–7.
7 Tavani A, Gallus S, La Vecchia C, Dal Maso L, Pelucchi C, Montella M, et al. Physical activity and risk of ovarian cancer: An Italian case–control study. Int J Cancer. In press 2001.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. A. Mucci, P. W. Dickman, M. Lambe, H.-O. Adami, D. Trichopoulos, T. Riman, C.-c. Hsieh, and S. Cnattingius Gestational Age and Fetal Growth in Relation to Maternal Ovarian Cancer Risk in a Swedish Cohort Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1828 - 1832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Liu, M. Lambe, I. Baik, S. Cnattingius, T. Riman, A. Ekbom, H.-O. Adami, and C.-C. Hsieh A Prospective Study of the Transient Decrease in Ovarian Cancer Risk Following Childbirth Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2508 - 2513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lukanova and R. Kaaks Endogenous Hormones and Ovarian Cancer: Epidemiology and Current Hypotheses Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 98 - 107. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||